Capnia with offices in Hong Kong and Foster City, CA recently hired the team at BioPortUSA to conduct a Discovery Session. The purpose of this session is to run the client through a SWOT analysis, Competitor Profile and a Client Profile. According to Mark Lesselroth, CEO of BioPortUSA “we have found this exercise to be extremely valuable in helping our clients better understand how to navigate the U.S. Healthcare market..” At the conclusion, a path to market is established, and if the client is interested in selling under their own brand, then the results of this session provide the marketing team a good reference point on what they should focus on in an effort to promote the brand.
Capnia’s main product, the CoSense End-Tidal Carbon Monoxide (ETCO) Monitor is utilized for the detection of a dangerous hemolysis in newborns. The product has also shown promise for smoking cessation, sickle cell anemia and for the detection of carbon monoxide poisoning. In the coming weeks, BioPortUSA looks forward to assisting the management of Capnia in successfully commercializing their product in the United States.